King® Guide to Parenteral Admixtures®

Online Edition

Welcome to the King Guide to Parenteral Admixtures Internet Edition.

Enter Login Information



Now Available!
COVID-19 Vaccine Product & Stability Information

License Agreement


Summer 2021

In this update we added new monographs for for COVID-19 VACCINE (JANSSEN), TAFASITAMAB-CXIX, and VILTOLARSEN.

We also added new stability information to these existing drug monographs:  AMIODARONE HYDROCHLORIDE, AZTREONAM, CEFEPIME HYDROCHLORIDE, CEFTAZIDIME, COVID-19 VACCINE (PFIZER-BIONTECH), IMIPENEM-CILASTATIN, ISOSORBIDE DINITRATE, KETAMINE HYDROCHLORIDE, LORAZEPAM, MEROPENEM, PIPERACILLIN AND TAZOBACTAM, and VALPROATE SODIUM.

New compatibility information was added to these existing drug monographs: ALPROSTADIL, CALCIUM GLUCONATE, CEFAZOLIN SODIUM, CEFTAZIDIME, CISATRACURIUM BESYLATE, DEXMEDETOMIDINE HYDROCHLORIDE, DOBUTAMINE HYDROCHLORIDE, DOPAMINE HYDROCHLORIDE, EPINEPHRINE HYDROCHLORIDE, FUROSEMIDE, GENTAMICIN SULFATE, INSULIN, REGULAR, TRAMADOL HYDROCHLORIDE, KETAMINE HYDROCHLORIDE, MIDAZOLAM HYDROCHLORIDE, MILRINONE HYDROCHLORIDE, NOREPINEPHRINE BITARTRATE, ONDANSETRON HYDROCHLORIDE, PERITONEAL DIALYSIS SOLUTIONS, and VANCOMYCIN HYDROCHLORIDE.

  © 2021 - King Guide Publications, Inc. All rights reserved.